- Home
- ENGN vs CYBN Comparison
ENGN vs CYBN Comparison
Compare ENGN & CYBN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENGN
- CYBN
- Stock Information
- Founded
- ENGN 1999
- CYBN 2019
- Country
- ENGN Canada
- CYBN Canada
- Employees
- ENGN N/A
- CYBN N/A
- Industry
- ENGN
- CYBN Pharmaceuticals and Biotechnology
- Sector
- ENGN
- CYBN Health Care
- Exchange
- ENGN Nasdaq
- CYBN Nasdaq
- Market Cap
- ENGN 191.1M
- CYBN 180.4M
- IPO Year
- ENGN N/A
- CYBN N/A
- Fundamental
- Price
- ENGN $3.37
- CYBN $7.61
- Analyst Decision
- ENGN Buy
- CYBN Strong Buy
- Analyst Count
- ENGN 7
- CYBN 4
- Target Price
- ENGN $23.29
- CYBN $85.00
- AVG Volume (30 Days)
- ENGN 83.9K
- CYBN 387.1K
- Earning Date
- ENGN 09-09-2025
- CYBN 08-07-2025
- Dividend Yield
- ENGN N/A
- CYBN N/A
- EPS Growth
- ENGN N/A
- CYBN N/A
- EPS
- ENGN N/A
- CYBN N/A
- Revenue
- ENGN N/A
- CYBN N/A
- Revenue This Year
- ENGN N/A
- CYBN N/A
- Revenue Next Year
- ENGN N/A
- CYBN N/A
- P/E Ratio
- ENGN N/A
- CYBN N/A
- Revenue Growth
- ENGN N/A
- CYBN N/A
- 52 Week Low
- ENGN $2.65
- CYBN $4.81
- 52 Week High
- ENGN $11.00
- CYBN $13.88
- Technical
- Relative Strength Index (RSI)
- ENGN 40.69
- CYBN 46.51
- Support Level
- ENGN $2.95
- CYBN $7.35
- Resistance Level
- ENGN $3.98
- CYBN $7.85
- Average True Range (ATR)
- ENGN 0.27
- CYBN 0.60
- MACD
- ENGN 0.02
- CYBN -0.10
- Stochastic Oscillator
- ENGN 34.29
- CYBN 18.20
About ENGN enGene Holdings Inc.
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.
About CYBN Cybin Inc.
Cybin Inc is a biopharmaceutical company involved in creating safe and effective therapeutics for patients to address a multitude of mental health issues. The company is focused on advancing psychedelic-based therapies, delivery mechanisms, novel compounds, and protocols as potential treatments for various psychiatric and neurological conditions.